DE69405714D1 - Hypolipidämische, kondensierte 1,4-thiazepine - Google Patents

Hypolipidämische, kondensierte 1,4-thiazepine

Info

Publication number
DE69405714D1
DE69405714D1 DE69405714T DE69405714T DE69405714D1 DE 69405714 D1 DE69405714 D1 DE 69405714D1 DE 69405714 T DE69405714 T DE 69405714T DE 69405714 T DE69405714 T DE 69405714T DE 69405714 D1 DE69405714 D1 DE 69405714D1
Authority
DE
Germany
Prior art keywords
carbon atoms
6alkyl
independently selected
hydrogen
pct
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69405714T
Other languages
English (en)
Other versions
DE69405714T2 (de
Inventor
Lawrence Brieaddy
Gordon Hodgson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellcome Foundation Ltd
Original Assignee
Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB939303014A external-priority patent/GB9303014D0/en
Priority claimed from GB939315154A external-priority patent/GB9315154D0/en
Application filed by Wellcome Foundation Ltd filed Critical Wellcome Foundation Ltd
Publication of DE69405714D1 publication Critical patent/DE69405714D1/de
Application granted granted Critical
Publication of DE69405714T2 publication Critical patent/DE69405714T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02—Seven-membered rings
    • C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02—Seven-membered rings
    • C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D281/10—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DE69405714T 1993-02-15 1994-02-15 Hypolipidämische, kondensierte 1,4-thiazepine Expired - Fee Related DE69405714T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB939303014A GB9303014D0 (en) 1993-02-15 1993-02-15 Hypolipidaemic compounds
GB939315154A GB9315154D0 (en) 1993-07-22 1993-07-22 Hypolipademic compounds
PCT/GB1994/000299 WO1994018183A1 (en) 1993-02-15 1994-02-15 Hypolipidaemic condensed 1,4-thiazepines

Publications (2)

Publication Number Publication Date
DE69405714D1 true DE69405714D1 (de) 1997-10-23
DE69405714T2 DE69405714T2 (de) 1998-01-29

Family

ID=26302466

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69405714T Expired - Fee Related DE69405714T2 (de) 1993-02-15 1994-02-15 Hypolipidämische, kondensierte 1,4-thiazepine

Country Status (14)

Country Link
US (1) US5817652A (de)
EP (1) EP0683773B1 (de)
JP (1) JPH08507049A (de)
AT (1) ATE158283T1 (de)
AU (1) AU6007794A (de)
CA (1) CA2156184A1 (de)
DE (1) DE69405714T2 (de)
DK (1) DK0683773T3 (de)
ES (1) ES2109672T3 (de)
GR (1) GR3025532T3 (de)
HU (1) HUT71613A (de)
IL (1) IL108634A0 (de)
TW (1) TW342388B (de)
WO (1) WO1994018183A1 (de)

Families Citing this family (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA956647B (en) * 1994-08-10 1997-02-10 Wellcome Found Hypolipidaemic compounds.
US5994391A (en) * 1994-09-13 1999-11-30 G.D. Searle And Company Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US6107494A (en) * 1994-09-13 2000-08-22 G.D. Searle And Company Substituted 5-aryl-benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US6262277B1 (en) 1994-09-13 2001-07-17 G.D. Searle And Company Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US6642268B2 (en) 1994-09-13 2003-11-04 G.D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
US6268392B1 (en) 1994-09-13 2001-07-31 G. D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
GB9423172D0 (en) * 1994-11-17 1995-01-04 Wellcom Foundation The Limited Hypolipidemic benzothiazepines
DE69815180T2 (de) * 1997-03-14 2004-04-29 Aventis Pharma Deutschland Gmbh Hypolipidemische 1,4-Benzothiazepin-1,1-dioxide
JPH11193289A (ja) * 1997-12-26 1999-07-21 Suntory Ltd ピロールスルホンアミド誘導体
EP1140189B1 (de) 1998-12-23 2003-05-14 G.D. Searle LLC. Kombinationen von ileumgallensäuretransports inhibitoren und fibronsäure derivaten für kardiovaskuläre indikationen
WO2000038722A1 (en) 1998-12-23 2000-07-06 G.D. Searle & Co. COMBINATIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS AND HMG CoA REDUCTASE INHIBITORS FOR CARDIOVASCULAR INDICATIONS
DK1140185T3 (da) 1998-12-23 2003-09-29 Searle Llc Kombinationer af cholesterylestertransferhæmmere og galdesyre kompleksdannende forbindelser til hjertekar indikationer
PT1140188E (pt) 1998-12-23 2003-10-31 Searle Llc Combinacoes de inibidores do transporte de acidos biliares do ileo e de inibidores da proteina de transferencia de esteres de colesterilo para doencas cardiovasculares.
IL143949A0 (en) 1998-12-23 2002-04-21 Searle Llc Combinations of cholesteryl ester transfer protein inhibitors and fibric acid derivatives for cardiovascular indications
ATE242007T1 (de) 1998-12-23 2003-06-15 Searle Llc Kombinationen von cholesteryl ester transfer protein inhibitoren und nicotinsäure derivaten für kardiovaskuläre indikationen
EA004877B1 (ru) 1998-12-23 2004-08-26 Джи.Ди.Сирл Ллс Сочетания ингибиторов транспорта желчных кислот в подвздошной кишке и агентов, секвестрирующих желчные кислоты, для сердечно-сосудистых показаний
DE19916108C1 (de) * 1999-04-09 2001-01-11 Aventis Pharma Gmbh Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung
GB9914745D0 (en) * 1999-06-24 1999-08-25 Knoll Ag Therapeutic agents
WO2001008685A1 (en) * 1999-07-30 2001-02-08 Vertex Pharmaceuticals Incorporated Acyclic and cyclic amine derivatives
JP2001196581A (ja) * 2000-01-17 2001-07-19 Oki Electric Ind Co Ltd 半導体装置および半導体装置の製造方法
SE0000772D0 (sv) 2000-03-08 2000-03-08 Astrazeneca Ab Chemical compounds
EP1286984A2 (de) 2000-03-10 2003-03-05 Pharmacia Corporation Verfahren zur herstellung von tetrahydrobenzothiepinen
US7879840B2 (en) 2005-08-25 2011-02-01 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7718644B2 (en) 2004-01-22 2010-05-18 The Trustees Of Columbia University In The City Of New York Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
US8022058B2 (en) 2000-05-10 2011-09-20 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7393652B2 (en) 2000-05-10 2008-07-01 The Trustees Of Columbia University In The City Of New York Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2)
US20020183307A1 (en) * 2000-07-26 2002-12-05 Tremont Samuel J. Novel 1,4-benzothiazephine and 1,5-benzothiazepine compounds as inhibitors of apical sodium co-dependent bile acid transport and taurocholate uptake
EG26979A (en) 2000-12-21 2015-03-01 Astrazeneca Ab Chemical compounds
GB0121337D0 (en) 2001-09-04 2001-10-24 Astrazeneca Ab Chemical compounds
GB0121622D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
GB0121621D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
BRPI0212346B1 (pt) 2001-09-08 2016-02-02 Albireo Ab Compostos derivados de benzotiadiazepina ou um sal farmaceuticamente aceitável do mesmo com efeito inibidor de transporte de ácido de bile ileal, processo para a preparação dos mesmos, uso destes, e, composição farmacêutica.
BR0213501A (pt) 2001-11-02 2004-08-24 Searle Llc Compostos de benzotiepina mono- e di-fluorada como inibidores de transporte de ácido biliar co-dependente de sódio apical (asbt) e captação de taurocolato
EP1465885A4 (de) 2002-01-17 2005-04-27 Pharmacia Corp Neue alkyl/arylhydroxy- oder ketothiepin-verbindungen als hemmer des apikalen natriumcoabhängigen gallensäuretransports (asbt) und taurocholat-aufnahme
GB0209467D0 (en) 2002-04-25 2002-06-05 Astrazeneca Ab Chemical compounds
GB0213669D0 (en) 2002-06-14 2002-07-24 Astrazeneca Ab Chemical compounds
US7312208B2 (en) 2002-08-28 2007-12-25 Asahi Kasei Pharma Corporation Quaternary ammonium compounds
EP1535913B1 (de) * 2002-08-28 2011-11-02 Asahi Kasei Pharma Corporation Neue quaternüre ammoniumverbindungen
US7544678B2 (en) 2002-11-05 2009-06-09 The Trustees Of Columbia University In The City Of New York Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)
GB0304194D0 (en) 2003-02-25 2003-03-26 Astrazeneca Ab Chemical compounds
US7148246B2 (en) 2003-02-27 2006-12-12 Sanofi-Aventis Deutschland Gmbh Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals
DE10308353A1 (de) 2003-02-27 2004-12-02 Aventis Pharma Deutschland Gmbh Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE10308351A1 (de) 2003-02-27 2004-11-25 Aventis Pharma Deutschland Gmbh 1,3-substituierte Cycloalkylderivate mit sauren, meist heterocyclischen Gruppen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE10308352A1 (de) 2003-02-27 2004-09-09 Aventis Pharma Deutschland Gmbh Arylcycloalkylderivate mit verzweigten Seitenketten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE10308355A1 (de) 2003-02-27 2004-12-23 Aventis Pharma Deutschland Gmbh Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
WO2004080283A2 (en) 2003-03-07 2004-09-23 The Trustees Of Columbia University, In The City Of New York Type 1 ryanodine receptor-based methods
GB0307918D0 (en) 2003-04-05 2003-05-14 Astrazeneca Ab Therapeutic use
US7829552B2 (en) 2003-11-19 2010-11-09 Metabasis Therapeutics, Inc. Phosphorus-containing thyromimetics
US8710045B2 (en) 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
US7241787B2 (en) 2004-01-25 2007-07-10 Sanofi-Aventis Deutschland Gmbh Substituted N-cycloexylimidazolinones, process for their preparation and their use as medicaments
US7973030B2 (en) * 2004-02-27 2011-07-05 Asahi Kasei Pharma Corporation Benzothiazepine and benzothiepine compounds
DE602004004631D1 (de) 2004-04-01 2007-03-22 Sanofi Aventis Deutschland Oxadiazolone, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Pharmazeutika
DE102005026762A1 (de) 2005-06-09 2006-12-21 Sanofi-Aventis Deutschland Gmbh Azolopyridin-2-on-derivate als Inhibitoren von Lipasen und Phospholipasen
US7704990B2 (en) 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
KR101260859B1 (ko) * 2008-03-03 2013-05-06 르 라보레또레 쎄르비에르 감마-아미노알킬벤젠으로부터 벤조티아제핀을 제조하는 방법
EP2314583B1 (de) * 2008-08-12 2015-02-25 Nippon Soda Co., Ltd. Nitrogeniertes heterozyklisches derivat sowie bakterizid-wirkstoff für landwirtschaft und gartenbau
AU2009304596A1 (en) * 2008-10-17 2010-04-22 Akaal Pharma Pty Ltd S1P receptors modulators
CN102316872B (zh) * 2008-11-26 2016-12-21 萨蒂奥根制药公司 治疗肥胖症和糖尿病的胆汁酸再循环抑制剂
US20120046364A1 (en) 2009-02-10 2012-02-23 Metabasis Therapeutics, Inc. Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use
JP5442021B2 (ja) * 2009-09-28 2014-03-12 日本曹達株式会社 含窒素ヘテロ環化合物およびその塩ならびに農園芸用殺菌剤
JP2011162472A (ja) * 2010-02-09 2011-08-25 Nippon Soda Co Ltd 含窒素ヘテロ環化合物またはその塩、ならびに農園芸用殺菌剤
JO3131B1 (ar) 2010-04-27 2017-09-20 Glaxosmithkline Llc مركبات كيميائية
ES2552657T3 (es) 2010-05-26 2015-12-01 Satiogen Pharmaceuticals, Inc. Inhibidores del reciclado de ácidos biliares y saciógenos para el tratamiento de diabetes, obesidad, y afecciones gastrointestinales inflamatorias
PL2637646T3 (pl) 2010-11-08 2017-01-31 Albireo Ab Kombinacja farmaceutyczna zawierająca inhibitor ibat i środek wiążący kwasy żółciowe
DK3400944T3 (da) 2010-11-08 2020-10-12 Albireo Ab Ibat-inhibitorer til behandling af leversygdomme
PL2771003T3 (pl) 2011-10-28 2017-10-31 Lumena Pharmaceuticals Llc Inhibitory ponownego wykorzystania kwasów żółciowych do leczenia pediatrycznych cholestatycznych chorób wątroby
CN104023718B (zh) 2011-10-28 2017-04-05 鲁美纳医药公司 用于治疗高胆血症和胆汁淤积性肝病的胆汁酸再循环抑制剂
MX2015013196A (es) 2013-03-15 2016-04-15 Lumena Pharmaceuticals Inc Inhibidores de reciclaje de acidos biliares para el tratamiento de la enfermedad de reflujo gastroesofagico y esofago de barrett.
CA2907230A1 (en) 2013-03-15 2014-09-18 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of primary sclerosing cholangitis and inflammatory bowel disease
JO3301B1 (ar) 2013-04-26 2018-09-16 Albireo Ab تعديلات بلورية على إيلوبيكسيبات
WO2015199147A1 (ja) 2014-06-25 2015-12-30 味の素株式会社 固形製剤及びその着色防止又は着色低減方法
AU2015298377B2 (en) 2014-08-05 2017-11-02 Glaxosmithkline Intellectual Property (No. 2) Limited Synthesis of benzothiazepines
EP3012252A1 (de) 2014-10-24 2016-04-27 Ferring BV Kristalline Form von elobixibat
US20160207893A1 (en) * 2014-12-30 2016-07-21 Myotherix, Inc. Novel calcium modulators
US10441605B2 (en) 2016-02-09 2019-10-15 Albireo Ab Oral cholestyramine formulation and use thereof
CA3011565C (en) 2016-02-09 2024-01-02 Albireo Ab Oral cholestyramine formulation and use thereof
EP3413878B1 (de) 2016-02-09 2021-04-14 Albireo AB Orale cholestyraminformulierungen und verwendung davon
US10441604B2 (en) 2016-02-09 2019-10-15 Albireo Ab Cholestyramine pellets and methods for preparation thereof
US10786529B2 (en) 2016-02-09 2020-09-29 Albireo Ab Oral cholestyramine formulation and use thereof
JP7328207B2 (ja) 2017-08-09 2023-08-16 アルビレオ・アクチボラグ コレスチラミンペレット、経口コレスチラミン製剤、及びそれらの使用
EP3664781A1 (de) 2017-08-09 2020-06-17 Albireo AB Cholestyramingranulate, orale cholestyraminformulierungen und ihre verwendung
TW202015699A (zh) 2018-06-05 2020-05-01 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽汁酸調節劑之用途
US10793534B2 (en) 2018-06-05 2020-10-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
SG11202012151XA (en) 2018-06-20 2021-01-28 Albireo Ab Crystal modifications of odevixibat
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
SG11202108566VA (en) 2019-02-06 2021-09-29 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
EP3921027B1 (de) 2019-02-06 2023-07-19 Albireo AB Benzothiadiazepinverbindungen und ihre verwendung als gallensäuremodulatoren
US10975045B2 (en) 2019-02-06 2021-04-13 Aibireo AB Benzothiazepine compounds and their use as bile acid modulators
US10941127B2 (en) 2019-02-06 2021-03-09 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
CN114096268A (zh) 2019-02-12 2022-02-25 米鲁姆制药公司 用于增加患有胆汁淤积性肝病的儿科受试者的生长的方法
PT4069360T (pt) 2019-12-04 2024-03-06 Albireo Ab Compostos de benzotia(di)azepina e a sua utilização como moduladores de ácido biliar
KR20220109450A (ko) 2019-12-04 2022-08-04 알비레오 에이비 벤조티아(디)아제핀 화합물 및 담즙산 조절제로서의 이의 용도
TW202134218A (zh) 2019-12-04 2021-09-16 瑞典商艾爾比瑞歐公司 苯并噻氮呯化合物及其作為膽酸調節劑之用途
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
CA3158184A1 (en) 2019-12-04 2021-08-10 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
TW202134220A (zh) 2019-12-04 2021-09-16 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途
EP4069359B1 (de) 2019-12-04 2024-01-03 Albireo AB Benzothia(di)azepinverbindungen und ihre verwendung als gallensäuremodulatoren
TW202134221A (zh) 2019-12-04 2021-09-16 瑞典商艾爾比瑞歐公司 苯并噻二氮呯化合物及其作為膽酸調節劑之用途
WO2021110884A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
EP4069361B1 (de) 2019-12-04 2024-01-03 Albireo AB Benzothia(di)azepinverbindungen und ihre verwendung als gallensäuremodulatoren
CA3186857A1 (en) 2020-08-03 2022-02-10 Per-Goran Gillberg Benzothia(di)azepine compounds and their use as bile acid modulators
WO2022029101A1 (en) 2020-08-03 2022-02-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
KR20230106651A (ko) 2020-11-12 2023-07-13 알비레오 에이비 진행성 가족성 간내 담즙정체증(pfic)을 치료하기 위한 오데빅시바트
JP2024500309A (ja) 2020-12-04 2024-01-09 アルビレオ エービー ベンゾチア（ジ）アゼピン化合物および胆汁酸モジュレータとしてのその使用
TW202313579A (zh) 2021-06-03 2023-04-01 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途
US20230398125A1 (en) 2022-06-09 2023-12-14 Albireo Ab Treating hepatitis
WO2024008766A1 (en) 2022-07-05 2024-01-11 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
WO2024121434A1 (en) 2022-12-09 2024-06-13 Albireo Ab Asbt inhibitors in the treatment of renal diseases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3362962A (en) * 1964-01-24 1968-01-09 Hoffmann La Roche Certain benzothiazepine derivatives
US4778791A (en) * 1986-05-16 1988-10-18 Tanabe Seiyaku Co., Ltd. Pharmaceutical composition for improving constitution of lipids in blood
GB9203347D0 (en) * 1992-02-17 1992-04-01 Wellcome Found Hypolipidaemic compounds
US5276025A (en) * 1992-09-09 1994-01-04 Merck & Co., Inc. Heterobicyclic sulfonamides

Also Published As

Publication number Publication date
EP0683773B1 (de) 1997-09-17
ATE158283T1 (de) 1997-10-15
HU9501808D0 (en) 1995-08-28
DK0683773T3 (da) 1998-02-16
GR3025532T3 (en) 1998-02-27
TW342388B (en) 1998-10-11
HUT71613A (en) 1996-01-29
EP0683773A1 (de) 1995-11-29
ES2109672T3 (es) 1998-01-16
CA2156184A1 (en) 1994-08-18
DE69405714T2 (de) 1998-01-29
WO1994018183A1 (en) 1994-08-18
JPH08507049A (ja) 1996-07-30
IL108634A0 (en) 1994-05-30
AU6007794A (en) 1994-08-29
US5817652A (en) 1998-10-06

Similar Documents

Publication Publication Date Title
DE69405714D1 (de) Hypolipidämische, kondensierte 1,4-thiazepine
PH30921A (en) Branched alkylamino derivatives of thiazole, processes for their preparation and pharmaceutical composition containing them.
MX9606136A (es) Inhibidores de enzimas.
EP1092435A4 (de) Antidiabetische medikamente
DK0874812T3 (da) Hidtil ukendte 2,3,5-trimethyl-4-hydroxyanilidderivater, fremstilling deraf og terapeutisk anvendelse deraf
TW243449B (de)
NO982873D0 (no) 1-metylkarbapenemderivater
EP0921122A4 (de) Neue epoxysuccinamid-derivate oder ihre salze
ES2019554A6 (es) Procedimiento para preparar n,n -ditrimetoxibenzoilpiperazinas sustituidas en posicion 2"
DK0635495T3 (da) Benzospiroalkenderivater, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende dem
DK0420224T3 (da) Anthihepatopatisk middel
KR930019683A (ko) 사이클릭 아미노메틸렌 비스포스포네이트 유도체
EA200001157A2 (ru) Новые замещенные производные (дигидро)бензоксазина и (дигидро)бензотиазина, способ их получения и содержащие их фармацевтические композиции
DE69409877T2 (de) Benzospiroalken-Derivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen
GR3035010T3 (en) New derivatives of glycylanilides, preparation and therapeutical application

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee